152 related articles for article (PubMed ID: 26458489)
21. Zerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-β1 signaling pathway.
Kim S; Lee J; Jeon M; Lee JE; Nam SJ
Oncotarget; 2016 Jan; 7(2):1544-58. PubMed ID: 26637807
[TBL] [Abstract][Full Text] [Related]
22. Triple-negative breast cancer survival in Iranian patients.
Aghili M; Lashkari M; Farrokhpey AH; Izadi S
Acta Med Iran; 2013 Sep; 51(8):560-6. PubMed ID: 24026994
[TBL] [Abstract][Full Text] [Related]
23. Identification of patients with node-negative, triple-negative breast cancer who benefit from adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy.
Wu CE; Chen SC; Lin YC; Lo YF; Hsueh S; Chang HK
Anticancer Res; 2014 Mar; 34(3):1301-6. PubMed ID: 24596377
[TBL] [Abstract][Full Text] [Related]
24. FAK activation is required for IGF1R-mediated regulation of EMT, migration, and invasion in mesenchymal triple negative breast cancer cells.
Taliaferro-Smith L; Oberlick E; Liu T; McGlothen T; Alcaide T; Tobin R; Donnelly S; Commander R; Kline E; Nagaraju GP; Havel L; Marcus A; Nahta R; O'Regan R
Oncotarget; 2015 Mar; 6(7):4757-72. PubMed ID: 25749031
[TBL] [Abstract][Full Text] [Related]
25. Predictive factors and patterns of recurrence in patients with triple negative breast cancer.
Steward L; Conant L; Gao F; Margenthaler JA
Ann Surg Oncol; 2014 Jul; 21(7):2165-71. PubMed ID: 24558065
[TBL] [Abstract][Full Text] [Related]
26. The TrkB+ cancer stem cells contribute to post-chemotherapy recurrence of triple-negative breast cancers in an orthotopic mouse model.
Yin B; Ma ZY; Zhou ZW; Gao WC; Du ZG; Zhao ZH; Li QQ
Oncogene; 2015 Feb; 34(6):761-70. PubMed ID: 24531713
[TBL] [Abstract][Full Text] [Related]
27. Somatic EP300-G211S mutations are associated with overall somatic mutational patterns and breast cancer specific survival in triple-negative breast cancer.
Bemanian V; Noone JC; Sauer T; Touma J; Vetvik K; Søderberg-Naucler C; Lindstrøm JC; Bukholm IR; Kristensen VN; Geisler J
Breast Cancer Res Treat; 2018 Nov; 172(2):339-351. PubMed ID: 30132219
[TBL] [Abstract][Full Text] [Related]
28. Identification of novel long non-coding RNAs in triple-negative breast cancer.
Shen X; Xie B; Ma Z; Yu W; Wang W; Xu D; Yan X; Chen B; Yu L; Li J; Chen X; Ding K; Cao F
Oncotarget; 2015 Aug; 6(25):21730-9. PubMed ID: 26078338
[TBL] [Abstract][Full Text] [Related]
29. BRCA mutations cause reduction in miR-200c expression in triple negative breast cancer.
Erturk E; Cecener G; Tezcan G; Egeli U; Tunca B; Gokgoz S; Tolunay S; Tasdelen I
Gene; 2015 Feb; 556(2):163-9. PubMed ID: 25445393
[TBL] [Abstract][Full Text] [Related]
30. Triple-Negative Breast Cancer in Ghanaian Women: The Korle Bu Teaching Hospital Experience.
Der EM; Gyasi RK; Tettey Y; Edusei L; Bayor MT; Jiagge E; Gyakobo M; Merajver SD; Newman LA
Breast J; 2015; 21(6):627-33. PubMed ID: 26547900
[TBL] [Abstract][Full Text] [Related]
31. Correlation between p53 and epidermal growth factor receptor expression in breast cancer classification.
Wang XZ; Liu Q; Sun JJ; Zuo WS; Hu DW; Ma SG; Mu DB; Yu ZY
Genet Mol Res; 2015 Apr; 14(2):4282-90. PubMed ID: 25966200
[TBL] [Abstract][Full Text] [Related]
32. MiR-27a modulates radiosensitivity of triple-negative breast cancer (TNBC) cells by targeting CDC27.
Ren YQ; Fu F; Han J
Med Sci Monit; 2015 May; 21():1297-303. PubMed ID: 25943633
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of ERRα suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin.
Wu YM; Chen ZJ; Liu H; Wei WD; Lu LL; Yang XL; Liang WT; Liu T; Liu HL; Du J; Wang HS
Oncotarget; 2015 Sep; 6(28):25588-601. PubMed ID: 26160845
[TBL] [Abstract][Full Text] [Related]
34. CIP4 promotes metastasis in triple-negative breast cancer and is associated with poor patient prognosis.
Cerqueira OL; Truesdell P; Baldassarre T; Vilella-Arias SA; Watt K; Meens J; Chander H; Osório CA; Soares FA; Reis EM; Craig AW
Oncotarget; 2015 Apr; 6(11):9397-408. PubMed ID: 25823823
[TBL] [Abstract][Full Text] [Related]
35. Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448.
Bamodu OA; Huang WC; Lee WH; Wu A; Wang LS; Hsiao M; Yeh CT; Chao TY
BMC Cancer; 2016 Feb; 16():160. PubMed ID: 26917489
[TBL] [Abstract][Full Text] [Related]
36. Pilot Study on MAGE-C2 as a Potential Biomarker for Triple-Negative Breast Cancer.
Zhao Q; Xu WT; Shalieer T
Dis Markers; 2016; 2016():2325987. PubMed ID: 27843173
[No Abstract] [Full Text] [Related]
37. Identification of a novel inhibitor of triple-negative breast cancer cell growth by screening of a small-molecule library.
Fujita T; Mizukami T; Okawara T; Inoue K; Fujimori M
Breast Cancer; 2014 Nov; 21(6):738-47. PubMed ID: 23456737
[TBL] [Abstract][Full Text] [Related]
38. Metabolic characterization of triple negative breast cancer.
Cao MD; Lamichhane S; Lundgren S; Bofin A; Fjøsne H; Giskeødegård GF; Bathen TF
BMC Cancer; 2014 Dec; 14():941. PubMed ID: 25495193
[TBL] [Abstract][Full Text] [Related]
39. Identification of sample-specific regulations using integrative network level analysis.
Liu C; Louhimo R; Laakso M; Lehtonen R; Hautaniemi S
BMC Cancer; 2015 Apr; 15():319. PubMed ID: 25928379
[TBL] [Abstract][Full Text] [Related]
40. Dual specificity phosphatase 4 gene expression in association with triple-negative breast cancer outcome.
Baglia ML; Cai Q; Zheng Y; Wu J; Su Y; Ye F; Bao PP; Cai H; Zhao Z; Balko J; Zheng W; Lu W; Shu XO
Breast Cancer Res Treat; 2014 Nov; 148(1):211-20. PubMed ID: 25281216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
